Guardian Pharmacy Services (GRDN) Q3 2026 earnings review
Guardian Pharmacy's sales dip, but its profit keeps climbing
Guardian Pharmacy, which supplies medicines to assisted-living homes, earned more even though its sales slipped. Sales fell 2% because a federal law cut some drug prices, but the number of residents it serves rose 7%. Core profit excluding one-offs climbed 24%, above what its own plan pointed to, so chief executive Fred Burke raised the full-year plan.
| Sales from businesses owned a year ago | −3.6% reported sales −1.7% from a year ago |
|---|---|
| Core profit, excluding one-offs | $33.9M +24% from a year ago |
| Residents served | 218,000 +7% from a year ago |
| Full-year core profit outlook | Raised $7M middle of the range: $137M, about 19% growth |
⚖️ Verdict: 🟢 Bullish
The story got better because Guardian again shielded its profit from the drug price cuts. Its gross margin, the share of sales left after buying medicines, reached 23%, and new pharmacies weighed less on profit. One caution: finance chief Will Mudd said gains this large will not repeat, and overhead grew faster than sales.
The question now is whether Guardian can do this again when the next Medicare price cuts arrive in January. Either its new insurer contracts carry over to those drugs, or it must win fresh terms every year. The outlook for next year, due with fourth-quarter results, will tell.
🐂 Bull Case
Gross Margin Rises Despite Drug Price Cuts
Guardian supplies medicines to care homes. In January, Medicare, the US health plan for people over 65, began paying lower prices for ten widely used drugs. A 2022 law, the Inflation Reduction Act (IRA), forced those cuts.
Guardian's gross margin climbed anyway, for a fourth straight quarter. Finance chief Will Mudd credited "improved reimbursement, ongoing purchasing initiatives, plan optimization efforts". Chief executive Fred Burke wants "a reimbursement model that better compensates us for the services we provide".
- Gross margin: 23.0%, against 19.8% a year ago
- Cost of medicines and delivery: 77.0% of sales, down 3.2 percentage points
- Gross profit: $85.2 million, up 14% from a year ago
This matters because the gain came from contracts and buying terms that put more weight on generic drugs, which make up over 90% of prescriptions. Burke said of that shift: "We're a long way toward that goal". But the next round of Medicare price cuts starts in January, and Guardian must win the same protection on those drugs.
What to watch: gross margin in the first quarter of 2027, the first period under the new cuts. A margin that holds near 23% would show the insurer contracts cover those drugs too.
Guardian Raised Its Profit Plan a Fourth Time
Guardian sets a yearly target for adjusted EBITDA, its core profit before interest, tax, depreciation and one-offs. By our math, the previous target implied only 4% to 7% growth for the second half.
The third quarter alone delivered 24% growth, above what that target implied. Mudd cited "stronger-than-expected third quarter performance" and lifted the target again, the fourth increase since Guardian first set it.
That says the earlier target was cautious, not that the gains will last. By our math the new one leaves about 11% growth for the fourth quarter, against a base that Guardian said included favorable insurer terms.
What to watch: full-year core profit, due with fourth-quarter results. A figure above the new range would make the profit target cautious for a second year running.
Guardian Takes Over Residents From a Mail-Order Rival
Guardian grows partly by buying small local pharmacies that serve care homes. It ended September with $119.7 million in cash and no debt, and chief operating officer David Morris said "our acquisition pipeline remains active".
This quarter it bought the customer files of Nautilus, a mail-order pharmacy serving assisted-living homes in 14 states. Guardian moved those residents into 18 of its own pharmacies, which eight new regional leaders now help coordinate.
Because the residents use spare capacity, the deal should lift profit quickly. Burke said "it is accretive quicker", meaning it adds to earnings sooner than a pharmacy purchase. But Mudd said "Nautilus did not meaningfully contribute to this quarter".
What to watch: whether Guardian finds more customer files like Nautilus to buy. Burke said such chances are rare, so a second deal would show the model can repeat.
🐻 Bear Case
Margin Gain Came From Drug Costs, Not Overhead
Chief executive Fred Burke said "Our margin improvement demonstrates the scalability of Guardian's operating model". Scale would show up in overhead, the selling, general and administrative costs that are mostly staff pay, falling as a share of sales.
- Overhead: 16.2% of sales, up 0.8 percentage points from a year ago
- Overhead excluding one-offs: 15.5% of sales, against 13.7%
- Staff pay excluding share awards: up 10% from a year ago
- Operating margin: 6.8%, up 2.4 percentage points
The whole margin gain came from the cost of medicines, while overhead took a bigger share of sales. Part of that is arithmetic, because lower drug prices shrink sales but not the work. Burke added that fuel for deliveries "remains elevated".
Against gross profit, overhead excluding one-offs eased slightly, so finance chief Will Mudd's "operating leverage" holds only on that measure. Mudd also said gains like these are "not something that we will see to this magnitude in the quarters going forward".
What to watch: overhead excluding one-offs as a share of sales in the fourth quarter. A share still near 15.5% would mean growth adds staff costs as fast as it adds sales.
Drug Price Cuts Push Sales Below Last Year
The Inflation Reduction Act (IRA), a 2022 law, let Medicare negotiate lower prices for ten branded drugs from January. So Guardian dispenses more prescriptions for less money, and its sales slipped.
- Underlying sales, from pharmacies owned a year ago: down 3.6% by our math
- Prescriptions dispensed: 8.1 million, up 11%
- Sales per resident: down 8% by our math
This matters because Medicare adds drugs to the list every year, and the next prices start in January. Guardian has not yet put a size on that round. Mudd's "high single digits" growth without the cuts also includes acquisitions, so the underlying pace runs lower.
What to watch: the dollar effect of the 2027 price cuts, a figure Guardian has not given. It will show how far reported sales trail prescription growth next year.
New Pharmacies Still Hold Down Profit Margin
Guardian keeps opening and buying pharmacies, and young sites earn lower margins until they mature. That drag lowers the core profit margin: adjusted EBITDA, or profit before interest, tax, depreciation and one-offs, as a share of sales.
Finance chief Will Mudd said the newer sites "dampened our Adjusted EBITDA margin by 44 basis points in the quarter", or 0.44 percentage points. The drag has eased for three quarters in a row.
But the easing may not last, because Guardian keeps adding sites, from Lexington to Van's. Chief operating officer David Morris said: "It may go back up, so it'll move around".
What to watch: the drag Mudd reports in the fourth quarter, the first with Van's. A return toward 0.8 points would mean expansion is absorbing the gains at older sites.
Risks this quarter didn't answer
Four standing concerns got no clear answer this quarter, so each still waits on a specific number or event before it moves either way.
- Bought versus won residents: Guardian serves 218,000 residents but does not say how many came with Nautilus and Wellness Concepts; that split would show true growth.
- Care-home occupancy: Burke cited assisted-living occupancy of 89% from NIC MAP, an industry data service; slower resident gains next quarter would revive the worry.
- Insider share sales: founders and staff locked up 29.9 million shares, about 80% of their holdings, until September 2027; sales from the rest would test alignment.
- Little room for a stumble: by our math the full-year plan needs fourth-quarter core profit of about $43.7 million; the next report shows whether Guardian delivers it.
👓 Other Themes
Flu Vaccine Program Starts the Season Well
Each autumn Guardian runs flu vaccine clinics for care-home residents and staff, and finance chief Will Mudd cited "a successful launch to this year's vaccine programs". Chief executive Fred Burke said the program does not track the wider flu season, because these residents are "virtually 100% vaccinated". Fourth-quarter sales will show the effect.
Burke Sees No Quick Change in Drug Policy
Asked about the midterm elections, chief executive Fred Burke said it is "too early to call" whether Washington will change the drug price rules. He described Medicare's drug benefit as "arguably the most popular of the government benefits". Burke also sees no effect on Guardian from the planned split of CVS.
💲 Other KPIs
Inventory built up while sales slipped, reaching $57.1 million at the end of September. By our math, stock on hand covers about 18 days of the cost of goods sold, against about 15 days a year ago. The figure has risen every quarter this year, and the build has absorbed $13.1 million of cash so far this year.
Free cash flow, the cash from operations left after spending on equipment, rose 71% from a year ago by our math. Suppliers helped: Guardian's unpaid bills to them grew $18.1 million in the quarter. Nine-month free cash flow reached $65.8 million, including an $8.5 million insurer settlement.
The share count barely moved, up 0.8% from a year ago. In March, Guardian used the cash from a new share sale to buy back the same number of shares from early holders, so the count stayed level. The last founder shares converted to ordinary Class A stock in September.
🔮 Guidance
Raised. The plan now has full-year sales roughly level with 2025 at the middle of the range, as price cuts offset prescription growth. By our math, that leaves fourth-quarter sales down about 2%, close to the third quarter's pace. Second raise this year: +$30M, then +$10M. The plan excludes deals not yet completed, and the year looks reachable.
Raised. The plan now has core profit, adjusted EBITDA excluding one-offs, up about 19% this year at the middle of the range. By our math, that leaves about 11% growth for the fourth quarter. Fourth raise, and the largest: +$5.5M, +$3M, +$5M, +$7M. If the year-to-date pace holds, the total reaches about $142 million by our math.
❓ Key Questions
How many new residents came from acquisitions?
Residents rose by 8,000 in the quarter, but the count includes Nautilus and Wellness Concepts. Without a split, readers cannot tell how fast Guardian wins residents in the homes and markets it already serves.
How large are next year's drug price cuts for Guardian?
Medicare's next round of negotiated prices starts in January. Guardian has not said which drugs hit its business, or whether the insurer terms that protected this year's margin also cover them.
How much of this year's margin gain will last?
Mudd said the reimbursement and purchasing gains will not repeat at this size. A split between lasting and one-time items would show the margin base Guardian carries into next year.
What will Guardian do with its growing cash pile?
Cash climbed about $30 million in the quarter, and Guardian carries no debt. Small deals like Van's use little of it, so a plan for the rest matters to owners.
Why did inventory build while sales fell?
Stock on hand has grown faster than sales all year and tied up cash. Guardian has not said whether vaccines, new pharmacies or purchasing deals explain the build.